JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M003203200 on May 9, 2000

J. Biol. Chem., Vol. 275, Issue 29, 22348-22354, July 21, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/29/22348    most recent
M003203200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hussaini, I. M.
Right arrow Articles by VandenBerg, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hussaini, I. M.
Right arrow Articles by VandenBerg, S. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phorbol 12-Myristate 13-Acetate Induces Protein Kinase Ceta -specific Proliferative Response in Astrocytic Tumor Cells*

Isa M. HussainiDagger §, Larry R. Karns, Griffith Vinton||, Joan E. CarpenterDagger , Gerard T. RedpathDagger , Julianne J. Sando||, and Scott R. VandenBergDagger

From the Departments of Dagger  Pathology (Neuropathology),  Biomedical Engineering, and || Pharmacology, University of Virginia, Charlottesville, Virginia 22908

Received for publication, April 13, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Protein kinase C (PKC) activation has been implicated in cellular proliferation in neoplastic astrocytes. The roles for specific PKC isozymes in regulating this glial response, however, are not well understood. The aim of this study was to characterize the expression of PKC isozymes and the role of PKC-eta expression in regulating cellular proliferation in two well characterized astrocytic tumor cell lines (U-1242 MG and U-251 MG) with different properties of growth in cell culture. Both cell lines expressed an array of conventional (alpha , beta I, beta II, and gamma ) and novel (theta  and epsilon ) PKC isozymes that can be activated by phorbol myristate acetate (PMA). Another novel PKC isozyme, PKC-eta , was only expressed by U-251 MG cells. In contrast, PKC-delta was readily detected in U-1242 MG cells but was present only at low levels in U-251 MG cells. PMA (100 nM) treatment for 24 h increased cell proliferation by over 2-fold in the U-251 MG cells, whereas it decreased the mitogenic response in the U-1242 MG cells by over 90%. When PKC-eta was stably transfected into U-1242 MG cells, PMA increased cell proliferation by 2.2-fold, similar to the response of U-251 MG cells. The cell proliferation induced by PMA in both the U-251 MG and U-1242-PKC-eta cells was blocked by the PKC inhibitor bisindolylmaleimide (0.5 µM) and the MEK inhibitor, PD 98059 (50 µM). Transient transfection of wild type U-251 with PKC-eta antisense oligonucleotide (1 µM) also blocked the PMA-induced increase in [3H]thymidine incorporation. The data demonstrate that two glioblastoma lines, with functionally distinct proliferative responses to PMA, express different novel PKC isozymes and that the differential expression of PKC-eta plays a determining role in the different proliferative capacity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Malignant astrocytomas, common brain tumors, have a high rate of cellular proliferation and a propensity to infiltrate regional and, ultimately, remote brain structures. This aggressive and invasive growth is the hallmark feature that confers high morbidity and mortality of these tumors. Malignant glioma cells have higher levels of PKC1 than non-neopastic astrocytes (1-4), suggesting that excessive PKC activity may significantly contribute to astroglial tumorigenicity. Tight regulation of PKC activity may control neoplastic glial proliferation (5).

PKC is a family of ubiquitous phospholipid-dependent enzymes involved in signal transduction pathways associated with a variety of cellular responses including cell growth and differentiation, gene expression, hormone secretion, and membrane function (6-10). The activities of both the conventional (alpha , beta I, beta II, and gamma ) and novel (µ, theta , epsilon , eta , and delta ) PKC isozymes are regulated by phorbol esters, diacylglycerols, and phospholipids. Conventional PKC isozymes require Ca2+ for activity, whereas novel PKC and atypical (lambda , zeta ) PKC isozymes are Ca2+-independent (11). The atypical PKC isozymes are not activated by diacylglycerol, a product of receptor-mediated phospholipid hydrolysis (12). The activation of PKC in various cell types may lead to the stimulation of tyrosine phosphorylation pathways, the activation of mitogen-activated protein (MAP) kinase pathway and c-fos induction, all of which may increase cellular proliferation (13-16). However, the exact molecular mechanisms and signaling pathways involving PKC isozymes in neural cell types are not well understood.

Both human and experimental rodent gliomas express multiple classes of PKC isozymes, including PKC-alpha , -beta , -gamma , -delta , -epsilon , -theta , -eta , and -zeta (17-21). In cultured human and rat glioma cells, the differential expression of specific isozymes accompanies alterations in both proliferative activity and phenotypic differentiation that are related to specific cell lineages. Despite the putative role(s) of PKC signaling in the invasive growth of gliomas, there are conflicting data as to how specific PKC isozyme(s) may affect this malignant growth (22). Although most studies have focused on the role of conventional PKC isozymes, particularly PKC-alpha , with reports of either increasing proliferation or blocking apoptosis in malignant astrocytic tumor cells, the differential expression of nonconventional PKC isozymes may account for the apparent contradictory biologic effects of phorbol ester treatment or the experimental overexpression of different PKC isozymes (23).

The relationship between the expression of a specific novel PKC isozyme and increased proliferative capacity in glioblastomas was examined in two well characterized glioblastoma cell lines with different growth phenotypes and opposite patterns of [3H]thymidine incorporation in response to PMA treatment. Stable expression of PKC-eta in a glioblastoma cell line not expressing this isozyme converted the transfectants into a PMA growth-stimulated phenotype. These data suggest that the different profiles of PKC isozymes may determine the type of biologic response to cytokines and other mitogenic stimuli acting via PKC signaling pathways. The differential expression of PKC-eta appears to determine the proliferative response of glioblastoma cells to PMA and thus may play a role in mediating the invasive growth of glioblastomas.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- PMA and tubulin antibody (DMA1) were purchased from Sigma. A cDNA probe and polyclonal antibody specific for human PKC-eta were from the American Tissue Culture Collection (Manassas, VA) and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), respectively. The phospho-specific antibody to dually phosphorylated extracellular signal-regulated kinase-1 and -2 (ERK1/ERK2) was obtained from Promega Corporation (Madison, WI). The specific PKC inhibitor, bisindolylmaleimide (BIM), and a mitogen-activated kinase effector kinase (MEK) inhibitor, PD 98059, are products of Calbiochem (San Diego, CA). Human PKC-eta sense (5'-cgaagggttgggtggatctcG-3') and antisense (5'-cgagatccacccaaccctcG-3') phosphorothioate oligonucleotides were synthesized by Operon Technologies, Inc. (Alameda, CA).

Cell Cultures-- Human U-251 MG and U-1242 MG cell lines were generously supplied by Dr. D. D. Bigner (Duke University) and Dr. A. J. Yates (Ohio State University), respectively. Both cell lines were originally isolated from astrocytic tumors that were designated as glioblastomas, and their characteristics were described previously (24-27). Although monolayer cultures of both cell lines have significant proliferative fractions in nonconfluent growth conditions, U-1242 MG cells demonstrate a relative contact inhibition at confluence that U-251 MG cells do not exhibit (data not shown). Both lines were regularly determined to be free of mycoplasma with reagents from Gen-Probe, Inc. (San Diego, CA). Cells were grown in minimal essential medium-alpha modification (alpha -MEM) with 10% defined fetal bovine serum (Hyclone, Logan, UH) and 20 µg/ml bovine zinc-insulin (25.7 IU/mg; Sigma). The cells were cultured to 100% confluence and passaged every 4-5 days, from an initial concentration of 6-8 × 103/cm2 in T-flasks or 6- or 24-well plates and cultured in astrocyte growth medium (AGM7, containing 5% fetal bovine serum) at 37 °C in 4.8% CO2, 90% relative humidity. Prior to assays, cultures that were 80-100% confluent were washed three times with serum-free medium before exposure to PMA (100 nM) in the presence or absence of BIM in serum-free growth medium. After different treatments, the medium was removed, and cells were examined by Western and Northern blot analyses, or [3H]thymidine was added to study proliferative responses.

Transfection of PKC-eta cDNA in U-1242 MG Cells and Oligonucleotides in U-251 MG Cells-- A 2.2-kilobase human PKC-eta cDNA fragment, with a complete coding sequence, was inserted into a pCI expression vector with a CMV promoter and SV40-neo resistance gene cassette. U-1242 MG cells were transfected with 5 µg/ml of the human PKC-eta cDNA or with empty vector (pCI-CMV that did not contain a cDNA insert) by incubation for 6 h with LipofectAMINE (4 µl/ml in serum-free alpha -MEM). The cells were then washed twice with serum-free alpha -MEM and cultured in 10% fetal calf serum-supplemented medium containing the aminoglycoside G418 (300 µg/ml). After 4 weeks, the cultures were screened for PKC-eta expression, and single cell clones were derived by limiting dilution. U-251 MG cells were transiently transfected with the sense and antisense human PKC-eta phosphorothioate oligo(deoxy)nucleotides (ODNs) in serum-free alpha -MEM for 4 h with Lipofectin (4 µl/ml in serum-free alpha -MEM). The cells were then washed twice with serum-free alpha -MEM and cultured in 10% fetal calf serum-supplemented medium. All experiments with ODNs were performed within 20 h of 10% fetal calf serum-supplemented alpha -MEM addition.

Western Blot Analysis-- For the detection of PKC isozyme or tubulin, the rinsed cultured cells were extracted with 1% Triton X-100, 0.2% Nonidet P-40 (Nonidet P-40) in the presence of 2 mM EDTA, 100 µM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, and 1 µg/ml aprotinin. Proteins were boiled for 5 min in SDS-polyacrylamide gel electrophoresis (PAGE) buffer and separated by SDS-PAGE on 10% polyacrylamide slabs. They were then electroblotted onto nitrocellulose-1 (Life Technologies, Inc.) and reacted with polyclonal and monoclonal antibodies specific to PKC isozyme and tubulin, respectively. The antibodies were detected with anti-rabbit and mouse peroxidase-conjugates and final detection was carried out with ECL (Amersham Pharmacia Biotech) as described by the manufacturer. MAP kinase phosphorylation was stimulated in cells that had been cultured in serum-free medium by incubation with PMA (100 nM) or epidermal growth factor (EGF; 25 ng/ml in serum free-medium) for 1-15 min. The incubation was terminated by the addition of ice-cold phosphate-buffered saline (137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, at pH 7.4) containing 0.2 mM sodium orthovanadate to the culture. Phosphate-buffered saline was then aspirated, and cells were solubilized with 1.0% Nonidet P-40, 50 mM HEPES, 100 mM NaCl, 2 mM EDTA, 1 µg/ml leupeptin, 2 µg/ml aprotinin, 0.4 mg/ml sodium fluoride, 5 mg/ml dithiothreitol, and 0.2 mM sodium orthovanadate. The Nonidet P-40 extract was centrifuged at 14,000 × g for 15 min, electrophoresed, and immunoblotted as described above with a polyclonal antibody specific for phosphorylated ERK1/ERK2 (1: 10,000). Densitometer and ImageQuant software (Molecular Dynamics) were used to quantitate the protein bands.

Northern Blot Analysis-- Total RNA was isolated from adherent cells using TRIZOL reagent (Life Technologies, Inc.) as a monophasic solution of phenol and guanidine isothiocyanate, as modified from the single-step RNA isolation method developed by Chomczynski and Sacchi (28). All total RNA samples were quantified by UV spectrophotometry (200 ± 25 µg/1 × 107 cells; the 260/280 ratio ranged between 1.6 and 1.75) and stored at -70 °C before use. Total RNA (20 µg) from control and treated glioblastoma cells was electrophoresed on 1% (w/v) agarose gels and electroblotted onto Zeta probe nylon membranes (Bio-Rad). A cDNA probe specific for human PKC-eta was cut with XbaI and separated on low melting Seaplaque agarose (FMC BioProducts, Rockland, ME). The probe (25 ng) was labeled with [alpha -32P]dCTP (50 µCi) using a random primed DNA labeling kit (Life Technologies, Inc.). Electroblotted RNA on nylon membranes was hybridized with the labeled cDNA fragment at 42 °C for 24 h. As a control for loading, membranes also were hybridized with labeled human specific phosphoglyceraldehyde dehydrogenase cDNA. PhosphoImager (Molecular Dynamics) analysis was used to quantitate the radioactive bands.

[3H]Thymidine Incorporation-- Relative rates of DNA synthesis were assessed by determination of [3H]thymidine incorporation into trichloroacetic acid-precipitable material. Cells were pulsed for 2 h with [3H]thymidine (2 µCi/ml) and then washed with phosphate-buffered saline. This was followed by 10-min washes with 10% trichloroacetic acid, first at 4 °C and then at 22 °C. Cells were then dissolved in 1 N NaOH and placed in Ready-Safe scintillation fluid. [3H]Thymidine incorporation was measured with a Beckman Liquid scintillation counter.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression and Regulation of PKC Isozymes in Astroglial Tumor Cells-- The basal expression of eight PKC isozymes was determined by Western blot analysis in the U-251 MG and U-1242 MG cells (Fig. 1). Both astrocytic cell lines expressed multiple conventional (alpha , beta I, and beta II) as well as novel (epsilon  and theta ) PKC isozymes. The beta I antibody appeared to cross react with beta II, the lower band in beta I blots. A doublet of PKC-eta -reactive band(s) was detected only in U-251 MG cells and not in U-1242 MG cells or cultured fetal human astrocytes (data not shown). PKC-delta was conspicuously present in U-1242 MG cells and only at trace levels in U-251 MG cells. Treatment with PMA (100 nM) for 48 h significantly decreased the basal expression of PKC-alpha , -beta , -epsilon , and -theta in both lines and PKC-delta in the U-1242 MG cells (Fig. 1). PMA treatment increased PKC-eta and had no significant effect on PKC-beta II in the U-251 MG cells. Following PMA treatment, PKC-eta was still not detectable in either U-1242 MG cells or cultured fetal human astrocytes (data not shown).


View larger version (14K):
[in this window]
[in a new window]
  		Fig. 1.   Western blot analysis of PKC isozymes in U-1242 MG and U-251 MG cells. Triton-solubilized astrocytic tumor cell lysates (200 µg of protein) before and after PMA (100 nM) treatment for 48 h were fractionated 10% polyacrylamide gels and electroblotted onto nitrocellulose. The nitrocellulose was then reacted with antibodies to different PKC isozymes, and the final detection was carried out with ECL.

The time course for PMA regulation of the PKC isozymes is shown in Fig. 2. PMA transiently increased the expression of most isozymes before causing the decrease that was observed at 24 h. The most intense and rapid responses to PMA were associated with the conventional isozymes (after approximately 2 h) compared with the later and more moderate responses of the novel isozymes (6-16 h). In U-251 MG cells, the expression of PKC-beta I and the two PKC-eta bands were greatly increased compared with that of other PKC isozymes. PMA treatment of U-251 MG cells increased the lower and upper PKC-eta bands by 1.7- and 4.3-fold, respectively. In U-1242 MG cells, PKC-alpha and -delta were more significantly up-regulated.


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 2.   Time course of the regulation of PKC isozyme expression by PMA in U-1242 MG (A) and U-251 MG (B) cells. Protein (200 µg) was fractionated by SDS-PAGE following treatment of astrocytic tumor cells with PMA (100 nM) for timed intervals. Proteins were transferred to nitrocellulose and reacted with primary antibodies to different PKC isozymes. Final detection was carried out with ECL.

Effect of PMA on [3H]Thymidine Incorporation in U-251 MG and U-1242 MG Cells-- As shown in Fig. 3, treatment with PMA had opposite effects on [3H]thymidine uptake in the two glioblastoma cell lines that expressed different profiles of the PKC isozymes. PMA increased [3H]thymidine uptake in U-251 MG cells (PKC-eta expressing) by 2.2-fold (Fig. 3A) and decreased [3H]thymidine uptake in U-1242 MG cells by 0.9-fold (PKC-eta deficient, Fig. 3B). Pretreatment of the cells with the PKC inhibitor BIM at 0.5 and 10 µM abrogated both types of PMA effect on [3H]thymidine uptake, i.e. the stimulation in U-251 MG cells or the inhibition in U-1242 MG cells (Fig. 3). EGF (25 ng/ml) increased [3H]thymidine incorporation by 1.7- and 1.9-fold in U-251 MG and U-1242 MG cells, respectively.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 3.   [3H]Thymidine incorporation in response to PMA in human glioblastoma cell lines. U-251 MG cells (A) or U-1242 MG cells (B) were treated with PMA (100 nM) in serum-free alpha -MEM in the presence and absence of a PKC inhibitor, BIM (0.5 µM) for 20 h. The cultures were then pulsed with [3H]thymidine (2 µCi/ml) for 2 h and assayed for radioactivity.

Stable Overexpression of PKC-eta Isozyme in U-1242 MG Cells-- To determine whether the 2.2-fold mitogenic response of U-251 MG cells to the PMA treatment was specifically mediated by PKC-eta , the PKC-eta -deficient U-1242 MG cells were transfected with a 2.2-kilobase human PKC-eta cDNA fragment containing a complete coding sequence inserted into a pCI expression vector with a CMV promoter and SV40-neo resistance gene cassette. U-1242 MG cells were transfected with PKC-eta or an empty vector and selected with G418 for 4 weeks. Cultures of cells transfected with PKC-eta cDNA demonstrated detectable basal levels of PKC-eta , as determined by Western and Northern blot analyses, whereas cells that were only transfected with empty vector (PCI) did not. Single cell cloning was performed by limiting dilution, and several clones of U-1242 MG that expressed PKC-eta (U-1242-PKC-eta ) were selected for further studies.

Representative Western and Northern blots of a stable clone of U-1242 MG that expressed PKC-eta are shown in Fig. 4. The PKC-eta antibody used in this study recognized a doublet of bands in U-251 MG cells, but only the lower molecular weight species was detected in the U-1242-PKC-eta cells. As shown in Fig. 4A, both PMA and EGF increased the expression of PKC-eta in the U-1242-PKC-eta clones and in U-251 MG cells. Treatment of the U-1242-PKC-eta clone with PMA (100 nM) also increased the PKC-eta mRNA (2.2 kilobases) (Fig. 4B). The stable transfection of PKC-eta in U-1242 MG cells did not alter the expression and PMA-induced regulation of beta II and gamma  (Fig. 4C).


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 4.   PKC-eta overexpression in U-1242 MG cells. A, Western blot analysis of cellular protein (200 µg/lane) was performed by SDS-PAGE. PKC-eta protein was detected with polyclonal antibody (sc-215) from Santa Cruz Biotechnology. DM1A monoclonal antibody (Sigma) was used to detect tubulin as a control for protein load. The pCI clone was from empty vector-transfected U-1242 MG cells. The PKC-eta clone was from U-1242 MG cells transfected with pCI-CMV-eta . U-251 MG cells express endogenous PKC-eta . The three astrocytic clones were treated with PMA or EGF for 20 h before proteins were extracted for immunoblotting. B, Northern blot analysis of U-1242-pCI and U-1242-PKC-eta clones. Total RNA (20 µg) from each clone was subjected to Northern blot analysis using [alpha -32P]dCTP-labeled probes for PKC-eta and phosphoglyceraldehyde dehydrogenase (loading control). C, Western blot analysis of cellular protein (200 µg/lane) from control and PMA (100 nM) treated U-1242-pCI and U-1242-PKC-eta cells. Blots were immunoblotted with antibodies against tubulin, PKC-beta II, and PKC-gamma . Cont, control; kb, kilobases.

Effect of PMA on [3H]Thymidine Uptake in U-1242-PKC-eta MG Cells-- Stable expression of PKC-eta in U-1242 MG cells dramatically reversed the inhibitory effects of PMA treatment on [3H]thymidine uptake in the U-1242 MG cells (PKC-eta -deficient). PMA increased the [3H]thymidine uptake in U-1242 PKC-eta overexpressing cells 2.2-fold, analogous to the PMA effect on wild type glioblastoma cells (U-251 MG) that expressed PKC-eta . Pretreatment of U-1242-PKC-eta cells with BIM (0.5 µM) completely abolished the stimulatory effect of PMA (Fig. 5), similar to the effect on U-251 MG cells (Fig. 3). In the clone that was transfected with an empty vector (without PKC-eta insert), treatment with PMA still decreased [3H]thymidine uptake.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 5.   Effect of PMA on [3H]thymidine incorporation in U-1242-pCI and U-1242-PKC-eta clones. Cultures of U-1242-pCI (A) or U-1242-PKC-eta (B) were treated with PMA (100 nM) in serum-free alpha -MEM in the presence and absence of a PKC inhibitor, BIM (0.5 µM) for 20 h. They were then pulsed with [3H]thymidine (2 µCi/ml) for 2 h and harvested for radioactivity determination. Cont, control.

Transient Knockdown of PKC-eta Expression in Wild Type U-251 MG Cells-- We synthesized the human version of the mouse PKC-eta antisense oligonucleotide that was successfully used to knock down the expression of PKC-eta mRNA in mouse Bend cells by Cooper et al. (29). To determine whether PKC-eta is necessary for the PMA-induced increases in cell proliferation in U-251 MG cells, we transiently knocked down expression of the isozyme with phosphothioate oligonucleotide (ODN) antisense and assessed its effect on [3H]thymidine incorporation. Fig. 6 shows the effect of treating U-251 MG cells for 24 h with sense and antisense ODNs. The control sense ODN (1 µM) had no apparent effect on PKC-eta expression or on the PMA-induced increase in cell proliferation, whereas the same concentration of the antisense ODN reduced the expression of the isozyme by over 80% (Fig. 6A) and abrogated the proliferative response of the cells to PMA (Fig. 6B). Other PKC isozymes (alpha , beta II and gamma ) were not affected by the PKC-eta ODN antisense.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of phosphorothioate ODN antisense on PKC-eta expression and [3H]thymidine incorporation in wild type U-251 MG cells. A, cells were pretreated with PKC-eta ODN antisense (1 µM) or sense (1 µM) for a total of 20 h, and cells lysates (200 µg) were immunoblotted for PKC-eta or other isozymes reactivity. B, U-251 MG cells were pretreated with PKC-eta ODN antisense (1 µM) or sense (1 µM) with and without PMA (100 nM) for 20 h. The cultures were then pulsed with [3H]thymidine (2 µCi/ml) for 2 h and harvested for radioactivity determination. Cont, control.

PMA Treatment, MAP Kinase Phosphorylation, and [3H]Thymidine Uptake-- Activation of MAP kinase (ERK1/ERK2) is often an important step in the signaling cascade that leads to cellular proliferation. Because stimulation of PKC activity has been shown to increase cell proliferation by both MAP kinase-dependent and -independent pathways, we assessed MAP kinase phosphorylation and the effect of an inhibitor, PD 98509, of the upstream kinase, MEK, on the astrocyte mitogenic response to PMA. Both ERK1 and ERK2 were phosphorylated in response to PMA in all of these glioblastoma cells (U-251 MG, U-1242 MG, empty vector control and U-1242 PKC-eta overexpressors), and this phosphorylation was blocked by BIM (Fig. 7A) and PD 98509 (Fig. 7B). These data indicated that the phosphorylation of ERK1/ERK2 by PMA was not exclusively mediated via PKC-eta , because the ERK1 and ERK2 were comparably phosphorylated in the PKC-eta -deficient cells (wild type U-1242 MG and pCI-CMV empty vector transfected U-1242).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 7.   Phosphorylation of MAP kinase by PMA in U-1242 MG, U-251 MG, U-1242-pCI, and U-1242-PKC-eta cultures. Cells were treated with PMA (100 nM) for 10 min in serum free alpha -MEM in the presence and absence of the PKC inhibitor BIM (0.5 µM) (A) or an inhibitor (PD 98509, 50 µM) of MEK (B). Protein (100 µg) from cytosol was resolved by SDS-PAGE under reducing conditions and immunoblotted with polyclonal antibodies against phosphorylated and total MAP kinase following transfer onto nitrocellulose membrane. The blots were then incubated with secondary anti-rabbit IgG conjugated to peroxidase and developed with ECL. Cont, control.

To assess the role(s) of MAP kinase activation in PKC-eta associated stimulation of [3H]thymidine uptake, both PKC-eta -expressing and -deficient cells were pretreated with PD 98509 (50 µM) for 10 min before the addition of PMA (100 nM), and [3H]thymidine uptake was determined after 20 h. The MEK inhibitor, PD 98509, significantly reduced the basal mitogenic response in all cell lines (U-251 MG, pCI-CMV U-1242 empty vector, and U-1242 PKC-eta overexpressors) but to different degrees. In both PKC-eta -expressing lines (U-251 MG and U-1242 PKC-eta overexpressors), basal levels were only reduced to 70-80% compared with the PKC-eta -deficient (pCI-CMV U-1242 empty vector) line, which was reduced to 41% of basal levels. In the U-1242 MG cells that overexpress PKC-eta , the stimulatory effect of PMA on [3H]thymidine uptake appears to be totally mediated via MAP kinase activation (Fig. 8A), because inhibition with PD 98509 abrogates the response. In contrast, the MAP kinase inhibitor was less effective in counteracting the mitogenic response in U-251 MG cells (Fig. 8B) and the inhibitory response in wt U-1242 MG cells. In both cases, the PMA actions on proliferation, either stimulation in the presence of PKC-eta or inhibition in the absence of PKC-eta , may be modified by the presence of other PKC isoform(s) in the two cell lines.


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 8.   Effect of MEK inhibition on PMA-induced [3H]thymidine incorporation in PKC-eta -expressing cells. U-1242-PKC-eta (A) or U-251 MG (B) cells were pretreated with the MEK inhibitor, PD 98509 (50 µM) for 10 min before PMA (100 nM) addition to the cultures for 20 h. The cultures were then pulsed with [3H]thymidine (2 µCi/ml) for 2 h and harvested for radioactivity determination. Cont, control.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Although previous studies have strongly implicated PKC in regulating the growth of glioblastomas (5, 30), there are conflicting data as to how it regulates the malignant phenotype(s) of a high proliferative rate and cellular invasiveness (22, 31, 32). The differential expression of PKC isozymes, each mediating diverse biologic functions, could account for the contrasting effects of phorbol esters on specific biologic activities in astrocytic tumors (33-35). Likewise, this PKC isozyme diversity also could account for the apparently different cellular responses following the expression or overexpression of specific PKC isozymes (18, 17, 36).

The responses of glioblastomas to therapy with relatively nonspecific PKC inhibitors in several clinical trials have been ambiguous. These outcomes suggested that the in situ growth of only certain, as yet undefined, tumor subgroups may be sensitive to the disruption of PKC signaling (23, 37). Previous in vitro studies with both human glioma and experimental rodent tumor cell lines have demonstrated that specific PKC isozymes may selectively affect astrocytic tumor growth. PKC-alpha has been implicated in proliferation or suppression of apoptosis (19). A role for PKC-gamma in augmenting anchorage-independent growth in cell culture has also been suggested (18).

Regulation of human astrocyte proliferation or apoptosis by the novel isozymes has not been clearly defined. PKC-epsilon appeared to affect the initial exit from the G0/G1 phase in human 132-1N1 astrocytoma cells (38), but PKC-alpha played the major determinant role for proliferation. PKCdelta overexpression decreased anchorage-independent growth in U-251 MG but did not affect basal or growth factor-stimulated proliferation (18).

We have found that both U-251 MG and U-1242 MG cells expressed PKC-alpha , -beta I, -beta II, -delta , and -theta but that PKC-eta was expressed only in the invasive U-251 MG cells (Fig. 1). Treatment of the cells with PMA for 24-48 h caused a decrease in expression of all isozymes, except that PKC-beta II and PKC-eta were up-regulated in the U-251 cells (Figs. 1 and 2). Prior to the decrease in isozyme expression detectable by Western blotting, some increase in expression was observed for most of the isozymes. The peak in expression tended to occur earlier (~2 h after PMA stimulation) for the classical, Ca2+-dependent isozymes and later (~6-16 h) for the novel, Ca2+-independent isozymes.

There is also a trend for PMA-induced up-regulation of PKC-eta or for the absence of down-regulation in other cell types. Unique up-regulation of PKC-eta has been noted previously in interleukin 2-producing EL4 mouse thymoma cells (12), in murine keratinocytes (39), and in breast cancer lines (40), and the lack of down-regulation was observed also in A431 human epidermal carcinoma cells (41). Basu (40) observed down-regulation of PKC-eta after treatment of MCF-7 cells with BIM, but we did not see a BIM-induced down-regulation of PKC-eta expression in the astrocytic cell lines (data not shown). In the astrocytic tumor cells studied here, it is notable that each cell line appears to up-regulate one classical isozyme and one novel isozyme significantly; but the predominant up-regulated isozymes differ: PKC-beta I and PKC-eta in U-251 MG cells and PKCalpha and PKC-delta in U-1242 MG cells. This may indicate involvement of different classes of isozymes in different phases of a biologic response and may suggest that other members of a class may mediate analogous early or late functions.

The biologic responses of U-251 MG and U-1242 MG cells to PMA differ. U-251 MG cells are growth-stimulated by PMA, whereas U-1242 MG cells are growth-inhibited (Fig. 3). The general PKC inhibitor BIM blocked the PMA-induced growth stimulation or growth-inhibition (Fig. 3), suggesting that PKC is responsible for both effects. The opposing effects may be attributable to the different isozymes expressed. Stable expression of PKC-eta in the U-1242 MG cells (Fig. 4) converted the PMA response from growth inhibition to growth stimulation like that of the U-251 cells (Fig. 5). The PMA-induced proliferative response in wild type U-251 MG cells was also completely blocked by PKC-eta phosphorothioate oligonucleotide antisense (Fig. 6). These results further argue for involvement of PKC-eta in the growth stimulatory response of the malignant astrocytic tumor cells to PMA. Although expression of PKC-eta correlates with a proliferative response of the astrocytoma cells, these isoform-specific trends are not present in different cell types. In EL4 thymoma cells, PKC-theta has been associated with growth stimulatory responses (12, 42), whereas PKC-eta has been implicated in morphological changes of EL4 cells (42) and NIH3T3 fibroblasts (44). There are no significant morphological differences between U-1242 MG cells and the U-1242-PKC-eta clone, but the U-251 MG and U-1242 MG cells are morphologically different. U-1242 MG monolayer cultures show contact inhibition at confluence, whereas U-251 MG cells do not.

A doublet of PKC-eta -immunoreactive bands was detected in the U-251 MG cells, whereas only the lower band was present in the U-1242 MG cells that were transfected with the PKC-eta expression construct. Similar differences have been described previously in other cell lines. A doublet of PKC-eta -reactive bands was present in EL4 thymoma cells that were responsive to phorbol esters (12, 43), whereas only the lower band of PKC-eta was observed in phorbol ester-resistant EL4 cells that had been infected with a Sinbis viral construct expressing PKC-eta . The relationship between the doublet bands is not clear. These may represent differences in phosphorylation, alternatively spliced forms, or even closely related isozymes. Correlation of the growth response of U-1242 MG cells with expression of the lower molecular weight PKC-eta -reactive band suggests that the protein of lower molecular mass is responsible for the mitogenic effects of PMA in these gliobalstoma cells.

The signaling pathways by which PKC-eta may up-regulate cell proliferation in human glioblastomas is not yet clear. In many cell types, the MAP kinase pathway has been implicated in the PMA-induced growth stimulatory response (45). The MAP kinase pathway is stimulated by PMA in the astrocytic tumor cells as indicated by phosphorylation of ERK1/ERK2 MAP kinases after PMA treatment and its blockade by both the PKC inhibitor BIM and the MEK inhibitor PD98059 (Fig. 6). The MEK inhibitor also diminished the proliferative response. Although PKC-eta may be sufficient for MAP kinase activation, it is not exclusively essential because MAP kinase phosphorylation occurred in the U-1242 MG cells that lack PKC-eta . The growth inhibition of U-1242 MG cells even with this ERK1/ERK2 phosphorylation argues that MAP kinase activation is not sufficient for a growth stimulatory response to PMA in this cell line. One possibility is that other PKC isozymes expressed by both U-251 MG and U-1242 MG may account for the MAP kinase phosphorylation but that these isozymes do not significantly mediate cell proliferation in astrocytomas or affect it only when PKC-eta also is expressed. A second possibility could be that another isozyme, such as PKC-delta , which is present at higher levels in U-1242 MG cells, blocks the proliferative response of MAP kinase activation, unless PKC-eta is co-expressed. The latter is consistent with the results of Mishima et al. (18), in which overexpression of PKC-delta decreased anchorage-independent growth (46).

EGF is another potent mitogen for astrocytoma cells and induces proliferation of both U-1242 MG and U-251 MG cells. EGF can activate PKC, but the proliferative response of U-1242 MG cells argues against the involvement of PKC-eta in the EGF effect. The effectiveness of EGF but not phorbol esters to induce a mitogenic response in U-1242 MG cells may suggest involvement of non-PKC pathways, such as tyrosine kinase activation, in EGF-induced mitogenesis and/or possibly atypical PKCs that are not activated by phorbol ester.

The functional characterization of PKC isozymes in human astrocytic tumors (17, 18, 21, 33, 37, 46, 47) has been impeded by the relative nonspecificity of PKC inhibitors and by the complex, differential expression of multiple isozymes. Animal cell lines may also have limited utility in the study of specific isozyme-associated biologic responses in human cells because these responses appear to differ between human and rodent cells (48). In the present studies, the overexpression of PKC-eta combined with the use of inhibitors and oligonucleotide antisense has implicated this novel PKC isozyme in PMA-induced proliferative activity. PKC-eta has a more limited tissue distribution than do many of the isozymes that have been previously implicated in up-regulating glial proliferation, with minimal expression in normal brain (49, 50). These distinctions make PKC-eta an excellent potential therapeutic target to control invasive tumor growth in human glioblastomas.

    FOOTNOTES

* This work was supported by Grants NS35122 (to I. M. H.) from NINDS, National Institutes of Health and GM31184 (to J. J. S.) from HHS, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Pathology (Neuropathology), University of Virginia, Charlottesville, VA 22908. Tel.: 804-924-9175; Fax: 804-924-9177; E-mail: imh5c@virginia.edu.

Published, JBC Papers in Press, May 9, 2000, DOI 10.1074/jbc.M003203200

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; MAP, mitogen-activated protein; PMA, phorbol myristate acetate; ERK, extracellular signal-regulated kinase; BIM, bisindolylmaleimide; MEK, mitogen-activated kinase effector kinase; alpha -MEM, minimal essential medium-alpha modification; CMV, cytomegalovirus; ODN, oligo(deoxy)nucleotide; PAGE, polyacrylamide gel electrophoresis; EGF, epidermal growth factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Todo, T., Shitara, N., Nakamura, H., Takakura, K., and Ikeda, K. (1991) Neurosurgery 108, 11-16
2. Benzil, D. L., Finkelstein, S. D., Epstein, M. H., and Finch, P. W. (1992) Cancer Res. 52, 2951-2956
3. Couldwell, W. T., Uhm, J. H., Antel, J. P., and Yong, V. W. (1991) Neurosurgery 29, 880-887
4. Couldwell, W. T., Antel, J. P., and Yong, V. W. (1992) Neurosurgery 31, 717-724
5. Baltuch, G. H., Dooley, N. P., Villemure, J.-G., and Yong, V. W. (1995) Can. J. Neurol. Sci. 22, 264-271
6. Nishizuka, Y. (1984) Nature 308, 693-698
7. Nishizuka, Y. (1988) Nature 334, 661-665
8. Basu, A. (1993) Pharmacol. Ther. 59, 257-280
9. Blobe, G. C., Obeid, L. M., and Hannun, Y. A. (1994) Cancer Metastasis Rev. 13, 411-431
10. Gescher, T. (1992) Br. J. Cancer 66, 10-19
11. Nishizuka, Y. (1995) FASEB J. 9, 484-496
12. Resnick, M. S., Luo, X., Vinton, G., and Sando, J. J. (1997) Cancer Res. 57, 2209-2215
13. Kaneki, M., Kharbanda, S., Pandey, P., Yoshida, K., Takekawa, M., Liou, J. R., Stone, R., and Kufe, D. (1999) Mol. Cell. Biol. 19, 461-470
14. Nakanishi, H., and Exton, J. H. (1992) J. Biol. Chem. 267, 16347-16354
15. Yu, S. M., Chen, S. F., Lau, Y. T., Yang, C. M., and Chen, J. C. (1997) Mol. Pharmacol. 50, 1000-1009
16. Bhat, N. R. (1995) Dev. Neurosci. 17, 267-284
17. Luo, W., Sharif, T. R., Houghton, P. J., and Sharif, M. (1997) Cell Growth Differ. 8, 1225-1240
18. Mishima, K, Ohno, S., Shitara, N., Yamaoka, K., and Suzuki, K. (1994) Biochem. Biophys. Res. Commun. 201, 363-372
19. Shen, L., and Glazer, R. I (1998) Biochem. Pharmacol. 55, 1711-1719
20. Asotra, K., and Macklin, W. B. (1994) J. Neurosci. Res. 39, 273-289
21. Chen, C. C., Wang, J. K., Chen, W. C., and Lin, S. B. (1998) J. Biol. Chem. 273, 19424-19430
22. Zellner, A., Fetell, M. R., Bruce, J. N., De Vivo, D. C., and O'Driscoll, K. R. (1998) Clin. Cancer Res. 4, 1797-1802
23. Guizzetti, M., Wei, M., and Costa, L. G. (1998) Eur. J. Pharmacol. 359, 223-233
24. Hussaini, I. M., Brown, M. D., Karns, L. R., Carpenter, J., Redpath, G. T., Gonias, S. L., and VandenBerg, S. R. (1999) Glia 25, 71-84
25. Bigner, D. D., Bigner, S. H., Ponten, J., Westermark, B., Mahaley, M. S., Ruoslahti, E., Herschman, H., Eng, L. F., and Wikstrand, C. J. (1981) J. Neuropath. Exp. Neurol. 40, 201-229
26. Bongcam-Rudloff, E., Nister, M., Betsholtz, C., Wang, J-L, Stenman, G., Huebner, K., Croce, C. M., and Westermark, B. (1991) Cancer Res. 51, 1553-1560
27. Uhrbom, L., Nister, M., and Westermark, B. (1997) Oncogene 15, 505-514
28. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-161
29. Cooper, S. R., Taylor, J. K., Miraglia, L. J., and Dean, N. M. (1999) Pharmacol. Ther. 82, 427-435
30. Sharif, T. R., and Sharif, M. (1999) Int. J. Oncol. 14, 327-135
31. Baltuch, G. H., and Yong, V. W. (1996) Brain Res. 710, 143-149
32. Dooley, N. P., Baltuch, G. H., Groome, N., Villemure, J. G., and Yong, V. W. (1998) Neuroreport 9, 1727-1733
33. Szaniawska, B., Maternicka, K., Kowalczyk, D., Miloszewska, J., and Janik, P. (1996) Cancer Lett. 107, 205-209
34. Pollack, I. F., Randall, M. S., Kristofik, M. P., Kelly, R. H., Selker, R. G., and Vertosick, F. T. (1990) J. Neurosurg. 73, 98-105
35. Couldwell, W. T., Antel, J. P., Apuzzo, M. L. J., and Yong, V. W. (1990) J. Neurosurg. 73, 594-600
36. Mischak, H., Goodnight, J., Kolch, W., Martiny-Baron, G., Schaechtle, C., Kazanietz, M. G., Blumberg, P. M., Pierce, J. H., and Mushinski, J. F. (1993) J. Biol. Chem. 268, 6090-6096
37. Pollack, I. F., DaRosso, R. C., Robertson, P.L., Jakacki, R. L., Mirro, J. R., Jr, Blatt, J., Nicholson, S., Packer, R. J., Allen, J. C., Cisneros, A., and Jordan, V. C. (1997) Clin. Cancer Res. 3, 1109-1115
38. Couldwell, W. T., Hinton, D. R., Surnock, A. A., DeGiorgio, C. M., Weiner, L. P., Apuzzo, M. L., Masri, L., Law, R. E., and Weiss, M. H. (1996) Clin. Cancer Res. 2, 619-622
39. Denning, M. F., Dlugosz, A. A., Williams, E. K., Szallasi, Z., Blumberg, P. M., and Yupsa, S. H. (1995) Cell Growth Differ. 6, 149-157
40. Basu, A. (1998) Mol. Pharmacol. 53, 105-111
41. Greif, H., Ben-Chaim, J., Shimon, T., Bechor, E., Eldar, H., and Livneh, E. (1992) Mol. Cell. Biol. 12, 1304-1311
42. Baier-Bitterlich, G., Uberall, F., Bauer, B., Fresser, F., Wachter, H., Grunicke, H., Utermann, G., Alterman, A., and Baier, G. (1996) Mol. Cell. Biol. 16, 1842-1850
43. Resnick, M. S., Kang, B-S., Luu, D., Wickham, J. T., Sando, J. J., and Hahn, C. S. (1998) J. Biol. Chem. 273, 27654-27661
44. Livneh, E., Shimon, T., Bechor, E., Doki, Y., Schieren, I., and Weinstein, I. B. (1996) Oncogene 12, 1545-1555
45. Slevin, M., Krupinski, J., Kumar, S., and Gaffney, J. (1998) Lab. Invest. 78, 987-1003
46. Brodie, C., Kuperstein, I., Acs, P., and Blumberg, P.M. (1998) Mol. Brain Res. 56, 108-117
47. Brodie, C., Bogi, K., Acs, P., Lorenzo, P. S., Baskin, L., and Blumberg, P. M. (1998) J. Biol. Chem. 273, 30713-30718
48. Hoffman, J., Whittle, S., and Toews, M. (1996) J. Lipid Mediators Cell Signaling 13, 51-62
49. Osada, S., Mizuno, K., Saido, T. C., Akita, Y., Suzuki, K., Kuroki, T., and Ohno, S. (1990) J. Biol. Chem. 265, 22434-22440
50. Bacher, N., Zisman, Y., Berent, E., and Livneh, E. (1991) Mol. Cell. Biol. 11, 126-133

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
I. M. Hussaini, C. Trotter, Y. Zhao, R. Abdel-Fattah, S. Amos, A. Xiao, C. U. Agi, G. T. Redpath, Z. Fang, G. K.K. Leung, et al.
Matrix Metalloproteinase-9 Is Differentially Expressed in Nonfunctioning Invasive and Noninvasive Pituitary Adenomas and Increases Invasion in Human Pituitary Adenoma Cell Line
Am. J. Pathol., January 1, 2007; 170(1): 356 - 365.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Amos, P. M. Martin, G. A. Polar, S. J. Parsons, and I. M. Hussaini
Phorbol 12-Myristate 13-Acetate Induces Epidermal Growth Factor Receptor Transactivation via Protein Kinase C{delta}/c-Src Pathways in Glioblastoma Cells
J. Biol. Chem., March 4, 2005; 280(9): 7729 - 7738.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. E. Elagib, M. Xiao, I. M. Hussaini, L. L. Delehanty, L. A. Palmer, F. K. Racke, M. J. Birrer, G. Shanmugasundaram, M. A. McDevitt, and A. N. Goldfarb
Jun Blockade of Erythropoiesis: Role for Repression of GATA-1 by HERP2
Mol. Cell. Biol., September 1, 2004; 24(17): 7779 - 7794.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Sonnemann, V. Gekeler, A. Sagrauske, C. Muller, H.-P. Hofmann, and J. F. Beck
Down-regulation of protein kinase C{eta} potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells
Mol. Cancer Ther., July 1, 2004; 3(7): 773 - 781.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Nakata
Stimulation of Extracellular Signal-Regulated Kinase Pathway by Suramin with Concomitant Activation of DNA Synthesis in Cultured Cells
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 744 - 753.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Chattopadhyay, R. J. MacLeod, J. Tfelt-Hansen, and E. M. Brown
1alpha ,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells
Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E219 - E227.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. Junoy, H. Maccario, J.-L. Mas, A. Enjalbert, and S. V. Drouva
Proteasome Implication in Phorbol Ester- and GnRH-Induced Selective Down-Regulation of PKC ({alpha}, {epsilon}, {zeta}) in {alpha}T3-1 and L{beta}T2 Gonadotrope Cell Lines
Endocrinology, April 1, 2002; 143(4): 1386 - 1403.
[Abstract] [Full Text] [PDF]